Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Conditions
Interventions
Entospletinib MM
Entospletinib SDD
Locations
48
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Oncology Associates
Tucson, Arizona, United States
City of Hope National Medical Center
Duarte, California, United States
Sharp Memorial Hospital
San Diego, California, United States
Rocky Mountain Cancer Centers, LLP
Boulder, Colorado, United States
Kaiser Permanente of Colorado
Denver, Colorado, United States
Start Date
March 14, 2013
Primary Completion Date
September 14, 2017
Completion Date
January 30, 2020
Last Updated
November 19, 2020
NCT06846671
NCT07218341
NCT07030400
NCT05139017
NCT05529069
NCT06263491
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions